Abstract Book ESMO 22Nd World Congress on Gastrointestinal Cancer, 2020 Virtual
Total Page:16
File Type:pdf, Size:1020Kb
Abstract Book ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual 1-4 July 2020 Guest Editors: Scientific Committee, ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual Publication of this Abstract book is supported by Imedex, an HMP Company. An Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology Editor-in-Chief Deputy Editor F. André, Villejuif, France D. G. Haller, Philadelphia, Pennsylvania, USA Associate Editors Urogenital tumors Gynecological tumors Onco-Immunology G. Attard, Sutton, UK B. Monk, Phoenix, Arizona, USA P. Ascierto, Naples, Italy S. Pignata, Naples, Italy Gastrointestinal tumors Molecular and surgical pathology Melanoma D. Arnold, Hamburg, Germany I. I. Wistuba, Houston, Texas, USA G. Long, Sydney, Australia J. Tabernero, Barcelona, Spain Hematological malignancies Early drug development A. Cervantes, Valencia, Spain K. Tsukasaki, Saitama, Japan C. Massard, Villejuif, France Breast tumors Supportive care Liaison with ESMO F. André, Villejuif, France K. Jordan, Heidelberg, Germany P. Garrido, Madrid, Spain C. Sotiriou, Brussels, Belgium Epidemiology Industry corner: perspectives and controversies K. Dhingra, New York, New York, USA Thoracic tumors P. Boffetta, New York, New York, USA M. D. Hellmann, New York, New York, USA P. Lagiou, Athens, Greece Methodology S. Peters, Lausanne, Switzerland Preclinical and experimental science L. Belin, Paris, France J. F. Vansteenkiste, Leuven, Belgium T. U. E. Helleday, Sheffield, UK D. Giannarelli, Rome, Italy S. Yano, Kanazawa, Japan Precision medicine A. Hinke, Düsseldorf, Germany C. Swanton, London, UK V. Moreno, Barcelona, Spain Head and neck tumors Bioinformatics Social media A. T. C. Chan, Shatin, Hong Kong N. McGranahan, London, UK P. Aftimos, Brussels, Belgium Editorial Board M. S. Aapro, Genolier, Switzerland C. Ishioka, Sendai, Japan S. I. Ou, Orange, California, USA M. Alsina, Barcelona, Spain H. Iwata, Aichi, Japan C. Pezaro, Melbourne, Australia Y. Ando, Nagoya, Japan F. Janku, Houston, Texas, USA P. Pfeiffer, Odense, Denmark I. Barnes, Oxford, UK N. Katsumata, Kawasaki, Japan S. Postel-Vinay, Villejuif, France J. Bellmunt, Boston, Massachusetts, USA T. Kawaguchi, Osaka, Japan A. Psyrri, New Haven, Connecticut, USA B. Besse, Villejuif, France N. Kiyota, Kobe, Japan D. Quinn, Los Angeles, California, USA J. Beyer, Zurich, Switzerland C. La Vecchia, Milan, Italy S. S. Ramalingam, Atlanta, Georgia, USA J.-Y. Blay, Lyon, France P. N. Jr Lara, Sacramento, California, USA M. Reck, Grosshansdorf, Germany C. Bokemeyer, Hamburg, Germany J. M. Larkin, London, UK B. Rini, Cleveland, Ohio, USA E. Bria, Verona, Italy S. Loi, Melbourne, Australia R. Rosell, Badalona, Spain E. F. Burgess, Charlotte, North Carolina, USA S. Loibl, Neu-Isenburg, Germany A. D. Roth, Geneva, Switzerland P. G. Casali, Milan, Italy F. Lordick, Leipzig, Germany S. Saji, Fukushima, Japan F. Ciardiello, Naples, Italy Y. Loriot, Villejuif, France R. Salazar, Barcelona, Spain A. Comandone, Turin, Italy D. Lorusso, Milan, Italy T. Sato, Osaka, Japan P. G. Corrie, Cambridge, UK T. Macarulla Mercade, Barcelona, Spain M. Scartozzi, Ancona, Italy J. Cortés, Madrid, Spain M. Martin Jimenez, Madrid, Spain N. Schmitz, Hamburg, Germany G. Curigliano, Milan, Italy S. Matsui, Tokyo, Japan H.-J. Schmoll, Halle, Germany A. Di Leo, Prato, Italy J. Maurel, Barcelona, Spain Q. Shi, Rochester, Minnesota, USA R. Dienstmann, Barcelona, Spain G. McArthur, Melbourne, Australia A. F. Sobrero, Genoa, Italy T. Dorff, Los Angeles, California, USA F. Meric-Bernstam, Houston, Texas, USA G. Sonpavde, Birmingham, Alabama, USA A. Eniu, Cluj-Napoca, Romania S. Michiels, Villejuif, France V. Subbiah, Houston, Texas, USA B.-C. Goh, Singapore, Singapore H. Minami, Kobe, Japan S. Takahashi, Tokyo, Japan A. Goldhirsch, Milan, Italy T. S. K. Mok, Shatin, Hong Kong N. Turner, London, UK P. Grimison, Sydney, Australia M. Muto, Kyoto, Japan E. Van Cutsem, Leuven, Belgium A. Grothey, Rochester, Minnesota, USA Y. Nishimura, Osaka-Sayama, Japan Y.-L. Wu, Guangzhou, China S. Halabi, Durham, North Carolina, USA K. Nishio, Osaka-Sayama, Japan J. C.-H. Yang, Taipei, Taiwan D. M. Hyman, New York, New York, USA S. Novello, Turin, Italy T. Yoshino, Chiba, Japan M. Ignatiadis, Brussels, Belgium M. Ogura, Gifu, Japan A. X. Zhu, Boston, Massachusetts, USA D. H. Ilson, New York, New York, USA A. Ohtsu, Kashiwa, Japan A. Inoue, Sendai, Japan I. Okamoto, Fukuoka, Japan Editors Emeriti F. Cavalli, Bellinzona, Switzerland D. J. Kerr, Oxford, UK J.-C. Soria, Paris, France J. B. Vermorken, Edegem, Belgium Executive Editor: L. H. Rowett Editorial Office: P. Minotti Bernasconi, G. Porcu, Annals of Oncology, Via Ginevra 4, 6900 Lugano, Switzerland Annals of Oncology is covered in C.A.B. International, Current Clinical Cancer, Current Contents/Clinical Medicine®, Current Contents/Life Sciences, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE/Excerpta Medica, IBIDS, Index Medicus/MEDLINE, The International Monitor in Oncology, Medical Documentation Service, Science Citation Index® and Science Citation Index Expanded. Aims and Scope conform to correct scientific English may wish to use the English Language ’ Annals of Oncology, the journal of the European Society for Medical Oncology Editing service available from Elsevier s WebShop http://webshop.elsevier.com/ and the Japanese Society of Medical Oncology, provides rapid and efficient languageediting/ or visit our customer support site http://support.elsevier.com peer-review publications on innovative cancer treatments or translational work for more information. related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific Copyright Information © The European Society for Medical Oncology 2020. Published by Elsevier Ltd. interest on molecular targeted agents and new immune therapies), randomized All rights reserved trials (including negatives ones), top-level guidelines, and new fields currently . emerging as key components of personalized medicine, such as molecular This journal and the individual contributions contained in it are protected under pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, copyright, and the following terms and conditions apply to their use in addition surgery and pediatrics manuscripts can be considered if they display a clear to the terms of any Creative Commons or other user license that has been interaction with one of the fields above or are paradigm-shifting. applied by the publisher to an individual article: Photocopying: With a large international editorial board of experts who are leaders in their Single photocopies of single articles may be made for fields, Annals of Oncology aims at delivering the best communication on the fast personal use as allowed by national copyright laws. Permission is not moving, and continually evolving, global oncology landscape. required for photocopying of articles published under the CC BY license nor For a full and complete Guide for Authors, please go to www.annalsofoncology.org for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and pay- Author inquiries ment of a fee is required for all other photocopying, including multiple or Once a manuscript is submitted, you can follow manuscript developments from systematic copying, copying for advertising or promotional purposes, resale, your online account, at the Annals of Oncology online submission website and all forms of document delivery. Special rates are available for educational http://mc.manuscriptcentral.com/annonc. You can track your accepted article at institutions that wish to make photocopies for non-profit educational class- http://www.elsevier.com/trackarticle. You are also welcome to contact Cus- room use. tomer Support via http://support.elsevier.com. Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or Publication Information companies. Other than for articles published under the CC BY license, permis- Publication information: Annals of Oncology (ISSN 0923-7534) comprises 12 issues sion of the publisher is required for resale or distribution outside the sub- plus supplements in each volume, with volume 31 scheduled for 2020. Subscription scribing institution or company. prices are available upon request from the Publisher or from the Elsevier Customer For any subscribed articles or articles published under a CC BY-NC-ND Service Department nearest you or from this website (http://www.elsevier.com/ license, permission of the publisher is required for all other derivative works, locate/annonc). Subscriptions are accepted on a prepaid basis only and are including compilations and translations. entered on a calendar year basis. Issues are sent by standard mail (surface within Storage or Usage: Except as outlined above or as set out in the relevant user Europe, air delivery outside Europe). Priority rates are available upon request. license, no part of this publication may be reproduced, stored in a retrieval USA mailing notice system or transmitted in any form or by any means, electronic, mechanical, Annals of Oncology (ISSN 0923-7534) is published monthly by (Elsevier Ltd, The photocopying, recording or otherwise, without prior written permission of the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK). USA